Systematic comparison of the performance of integrated whole-body PET/MR imaging to conventional PET/CT for 18F-FDG brain imaging in patients examined for suspected dementia

Journal of Nuclear Medicine

Volumn 55, Issue 6, 2014, Pages 923-931

  Hitz, Stefan ^a   Habekost, Cornelia ^a   Fur̈st, Sebastian ^a   Delso, Gaspar ^a   For̈ster, Stefan ^a,b   Ziegler, Sibylle ^a   Nekolla, Stephan G ^a   Souvatzoglou, Michael ^a   Beer, Ambros J ^a   Grimmer, Timo ^b   Eiber, Matthias ^b   Schwaiger, Markus ^a   Drzezga, Alexander ^a,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Brain imaging; Dixon MRI sequence; Neurodegeneration; PET CT; PET MR

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BASAL GANGLION; BRAIN RADIOGRAPHY; CEREBELLUM; CLINICAL ARTICLE; CLINICAL EVALUATION; COGNITIVE DEFECT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; FRONTAL CORTEX; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MALE; MIDDLE AGED; NEOCORTEX; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL CORTEX; PARIETAL CORTEX; PONS; PRIORITY JOURNAL; QUALITATIVE DIAGNOSIS; QUANTITATIVE DIAGNOSIS; SENSITIVITY ANALYSIS; TEMPORAL CORTEX; WHOLE BODY PET; BRAIN; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; IMAGE PROCESSING; IMAGE QUALITY; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; RADIOGRAPHY; SCINTISCANNING; WHOLE BODY IMAGING;

ADULT; AGED; BRAIN; DEMENTIA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIMODAL IMAGING; PHANTOMS, IMAGING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 84903188620     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.126813     Document Type: Article

References (37)

1. Hüll M, Berger M, Heneka M. Disease-modifying therapies in Alzheimer's disease: how far have we come? Drugs. 2006;66:2075-2093. (Pubitemid 46372359)
2. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1143-1153. (Pubitemid 32405708)
3. 18F]PET in mild and asymptomatic stages. Behav Neurol. 2009;21:101-115.
4. 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med. 2008;49:390-398.
5. Silverman DH, Gambhir SS, Huang HW, et al. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. J Nucl Med. 2002;43:253-266. (Pubitemid 34151051)
6. Van der Flier WM, Barkhof F, Scheltens P. Shifting paradigms in dementia: toward stratification of diagnosis and treatment using MRI. Ann N Y Acad Sci. 2007;1097:215-224. (Pubitemid 47084890)
7. Villemagne VL, Rowe CC, Macfarlane S, Novakovic KE, Masters CL. Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease. J Clin Neurosci. 2005;12:221-230. (Pubitemid 40585713)
8. Yuan Y, Gu ZX, Wei WS. Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis. AJNR. 2009;30:404-410.
9. Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002;17:302-316.
10. Joshi AD, Pontecorvo MJ, Clark CM, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects. J Nucl Med. 2012;53:378-384.
11. 11C-PIB uptake in Alzheimer's disease and MCI [abstract]. Alzheimers Dement. 2009;5(suppl):P50.
12. 18F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52:1210-1217.
13. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446-452.
14. Catana C, Drzezga A, Heiss WD, Rosen BR. PET/MRI for neurologic applications. J Nucl Med. 2012;53:1916-1925.
15. Martinez-Möller A, Souvatzoglou M, Delso G, et al. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med. 2009;50:520-526.
16. Veit-Haibach P, Kuhn FP, Wiesinger F, Delso G, von Schulthess G. PET-MR imaging using a tri-modality PET/CT-MR system with a dedicated shuttle in clinical routine. MAGMA. 2013;26:25-35.
17. Delso G, Furst S, Jakoby B, et al. Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med. 2011;52:1914-1922.
18. Eiber M, Martinez-Moller A, Souvatzoglou M, et al. Value of a Dixon-based MR/PET attenuation correction sequence for the localization and evaluation of PET-positive lesions. Eur J Nucl Med Mol Imaging. 2011;38:1691-1701.
19. Drzezga A, Souvatzoglou M, Eiber M, et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med. 2012;53:845-855.
20. 18F]FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36:2103-2110.
21. Pichler BJ, Judenhofer MS, Catana C, et al. Performance test of an LSO-APD detector in a 7-T MRI scanner for simultaneous PET/MRI. J Nucl Med. 2006;47:639-647. (Pubitemid 46768465)
22. Friston KJAJ, Frith CD, Poline JB, Heather JD, Frackowiak RSJ. Spatial registration and normalization of images. Hum Brain Mapp. 1995;2:165-189. (Pubitemid 3036540)
23. Kinahan PE,HasegawaBH,BeyerT.X-ray-based attenuation correction for positron emission tomography/computed tomography scanners. Semin Nucl Med. 2003;33:166-179. (Pubitemid 36859496)
24. Förster S, Grimmer T, Miederer I, et al. Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay. Biol Psychiatry. 2012;71:792-797.
25. 18F-FDG PET findings in frontotemporal dementia: an SPM analysis of 29 patients. J Nucl Med. 2005;46:233-239.
26. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36:1238-1248.
27. Bartenstein P, Minoshima S, Hirsch C, et al. Quantitative assessment of cerebral blood flow in patients with Alzheimer's disease by SPECT. J Nucl Med. 1997;38:1095-1101. (Pubitemid 27339617)
28. Kinahan PE, Townsend DW, Beyer T, Sashin D. Attenuation correction for a combined 3D PET/CT scanner. Med Phys. 1998;25:2046-2053.
29. Souvatzoglou M, Ziegler SI, Martinez MJ, et al. Standardised uptake values from PET/CT images: comparison with conventional attenuation-corrected PET. Eur J Nucl Med Mol Imaging. 2007;34:405-412. (Pubitemid 46295346)
30. Catana C, van der Kouwe A, Benner T, et al. Toward implementing an MRI-based PET attenuation-correction method for neurologic studies on the MR-PET brain prototype. J Nucl Med. 2010;51:1431-1438.
31. Andersen FL, Ladefoged CN, Beyer T, et al. Combined PET/MR imaging in neurology: MR-based attenuation correction implies a strong spatial bias when ignoring bone. Neuroimage. 2014;84:206-216.
32. Hofmann M, Steinke F, Scheel V, et al. MRI-based attenuation correction for PET/MRI: a novel approach combining pattern recognition and atlas registration. J Nucl Med. 2008;49:1875-1883.
33. Boss A, Bisdas S, Kolb A, et al. Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med. 2010;51:1198-1205.
34. Keereman V, Fierens Y, Broux T, De Deene Y, Lonneux M, Vandenberghe S. MRI-based attenuation correction for PET/MRI using ultrashort echo time sequences. J Nucl Med. 2010;51:812-818.
35. Johansson A, Karlsson M, Nyholm T. CT substitute derived from MRI sequences with ultrashort echo time. Med Phys. 2011;38:2708-2714.
36. Yakushev I, Landvogt C, Buchholz HG, et al. Choice of reference area in studies of Alzheimer's disease using positron emission tomography with fluorodeoxy-glucose-F18. Psychiatry Res. 2008;164:143-153.
37. Dukart J, Mueller K, Horstmann A, et al. Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies. Neuroimage. 2010;49:1490-1495.